What's Happening?
Artificial Intelligence (AI) is transforming regulatory medical writing, offering substantial efficiency improvements in clinical research. The PPD clinical research business of Thermo Fisher Scientific, for instance, has observed up to a 70% reduction
in patient lay summary cycle times, approximately 50% shorter master informed consent form timelines, and about 45% shorter clinical study report timelines when AI-assisted writing is combined with standardized review workflows. AI-enabled tools are creating opportunities to reduce manual effort and improve efficiency across the development lifecycle, from initial drafting and editorial reviews to quality checks and document consistency assessments. However, successful implementation requires careful consideration of how AI fits within existing workflows, who is responsible for scientific oversight, and how to maintain quality and regulatory compliance as processes evolve. This has led to various outsourcing models, including Functional Service Provider (FSP), Full-Service Outsourcing (FSO), and mixed FSP/FSO arrangements, to align AI technology with experienced medical writers and strong governance.
Why It's Important?
The adoption of AI in medical writing has significant implications for the U.S. pharmaceutical and biotechnology industries. The demonstrated efficiency gains can drastically reduce the time and cost associated with bringing new drugs and medical devices to market. This benefits companies by accelerating regulatory submissions and potentially increasing profitability. For patients, faster document processing means quicker access to innovative treatments and clearer, more concise information about clinical trials and their results. The emphasis on integrating AI with experienced medical writers and optimized processes, rather than relying solely on automation, highlights the critical role of human expertise in ensuring accuracy, scientific integrity, and regulatory compliance. This approach helps mitigate risks associated with AI while maximizing its benefits, impacting how clinical trials are managed and how medical information is communicated to both regulators and the public.
What's Next?
As AI capabilities mature, organizations will need to continuously adjust their outsourcing models to align with evolving needs, technological advancements, and regulatory landscapes. The challenge lies in structuring medical writing operations to realize the benefits of AI while adapting to future priorities. This involves evaluating existing expertise and technology infrastructure, defining control and accountability for AI-enabled workflows, and ensuring robust governance and regulatory compliance. The ability to build flexibility into an evolving AI strategy is essential for long-term value. This means that sponsors may shift between FSP, FSO, or mixed models depending on their internal capabilities, portfolio demands, and AI strategies. The ongoing integration of AI throughout the medical writing workflow, beyond just initial drafting, will continue to streamline processes, reduce bottlenecks, and allow medical writers to focus on higher-value scientific and strategic responsibilities.
Beyond the Headlines
The rise of AI in medical writing also brings forth deeper implications regarding the nature of work and the future of specialized professions. While AI can automate routine tasks, the need for human oversight, scientific interpretation, and ethical judgment remains paramount. This suggests a shift in the skill sets required for medical writers, emphasizing critical thinking, regulatory expertise, and the ability to effectively collaborate with AI tools. Furthermore, the reliance on AI for generating regulatory documents necessitates rigorous validation and auditing processes to ensure the accuracy and integrity of the information, especially given the potential for AI to propagate errors or biases if not properly managed. The ethical considerations around AI-generated content, particularly in patient-facing materials, will require ongoing attention to ensure clarity, transparency, and patient understanding without compromising scientific rigor.













